All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
LDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
HDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
Weight (kg) · adults with or without existing CVD
1 finding from 1 review
Body‐mass index (BMI) · adults with or without existing CVD
1 finding from 1 review
Cardiovascular mortality · adults with or without existing CVD
It is very uncertain whether higher changes cardiovascular mortality Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Cardiovascular events · adults with or without existing CVD
Higher showed no clear difference in cardiovascular events: any Study duration range 12‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
CHD events · adults with or without existing CVD
It is very uncertain whether higher changes CHD events: myocardial infarction (fatal or non‐fatal) or angina… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
MACCEs Study duration range 24‐96 months Omega‐6 dose range 2.8%‐12.0% E · adults with or without existing CVD
It is very uncertain whether higher changes MACCEs Study duration range 24‐96 months Omega‐6 dose range… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · adults with or without existing CVD
It is very uncertain whether higher changes stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E compared with lower omega‐6: additional key outcomes (low certainty).
1 finding from 1 review
Serum TC Study duration range 12‐96 months Omega‐6 dose range 2.0%‐24.5% E · adults with or without existing CVD
1 finding from 1 review
Serum TG Study duration range 12‐72 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
Adiposity · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Cholesterol mg/dL · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum fasting triglyceride (TG, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
HDL‐cholesterol · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum low‐density lipoprotein (LDL, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
CHD events · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease events compared with lower PUFA (moderate certainty).
1 finding from 1 review